Treatment with EMICORON, a synthetic compound binding to G4 structures, downregulated KRAS mRNA and protein expression in CRC cell lines, and decreased tumor volume in patient-derived xenografts bearing KRAS mutation. This evidence concerns the gene KRAS and neoplasm.